Ask AI
Advances in mCRPC

CE / CME

Advances in Metastatic Castration-Resistant Prostate Cancer: Biomarker-Driven Treatment Strategies and Emerging Therapeutic Approaches

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: July 20, 2026

Expiration: January 19, 2027

Activity

Progress
1 2 3
Course Completed

Which statement best describes the biologic rationale for how novel therapies such as BMS-986365 and ARV-766 may help overcome resistance to androgen receptor (AR) pathway inhibition in metastatic castration-resistant prostate cancer (mCRPC)?

All of the following investigational therapies have demonstrated activity in patients with mCRPC and AR ligand–binding domain mutations EXCEPT:

Which patient would be most appropriate to consider for referral to the phase III rechARge trial of BMS-986365?